SAN DIEGO, Calif. – June 17, 2024 – Primrose Bio, Inc. (“Primrose,” the “Company”), a company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines, announced a significant equity investment... The companies will leverage their combined experience in the development of conjugate vaccines for their clients Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development Intravacc has IP and know how in vaccine... SAN DIEGO, Sept. 18, 2023 /PRNewswire/ -- Primrose Bio, Inc., a stand-alone private biotechnology company focused on developing state-of-the-art discovery and production systems for protein and nucleic acid medicines, has been established as a... Primrose Bio Announces Investment from 1315 Capital to Advance Manufacturing Solutions for Next-Generation Therapeutics
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
Introducing Primrose Bio: Enabling Innovative Therapeutic Discovery and Manufacturing
Ligand signed a purchase and sale agreement with Primrose Bio and made an investment of $15m. The cross-pollination of platforms enables the San Diego-based company to create a novel way of enhancing productivity to enable the next generation of biological therapeutics Advancing the manufacture of protein and nucleic acid-based biologic vaccines and therapeutics
BPI News: Primrose Bio Blossoms from Pelican and Primordial Genetics Merger